American Medical Association's United States Adopted Names Council Has Approved And Adopted The Nonproprietary Drug Name Sozinibercept For Opthea's Lead Biologic Drug Candidate, OPT-302
Portfolio Pulse from Benzinga Newsdesk
The American Medical Association's United States Adopted Names Council has approved and adopted the nonproprietary drug name Sozinibercept for Opthea's lead biologic drug candidate, OPT-302.
July 26, 2023 | 10:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Opthea's lead biologic drug candidate, OPT-302, has been approved and adopted by the American Medical Association's United States Adopted Names Council under the nonproprietary name Sozinibercept.
The approval and adoption of the nonproprietary name for Opthea's lead drug candidate is a significant regulatory milestone. This could potentially increase the visibility and credibility of the drug, which may positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100